| Title |
Author |
Type |
Date |
Words |
| Hep C drug goes after patients' RNA: compound targets genetic material virus uses to replicate. |
Seppa, Nathan |
|
May 4, 2013 |
371 |
| UAE charities recognised for helping patients with Hepatitis C. |
|
|
May 3, 2013 |
374 |
| Liver transplants: Driven by desperation. |
|
|
Apr 28, 2013 |
2098 |
| Boehringer Ingelheim's Faldaprevir-Based Treatment Regimen Achieved Viral Cure in up to 80 Percent of Patients with Hepatitis C in Phase 3 Pivotal Trial. |
|
|
Apr 23, 2013 |
1648 |
| High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-NaE[macron]ve Patients with Genotype 1 Chronic Hepatitis C Infection. |
|
|
Apr 23, 2013 |
1852 |
| Findings from Two Phase 3 Studies of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients. |
|
|
Apr 23, 2013 |
1853 |
| Oakridge mourns advocate. |
|
|
Apr 19, 2013 |
1251 |
| Health minister told of man's contaminated blood. |
|
|
Apr 18, 2013 |
204 |
| Aethlon Medical (AEMD) Note: New Government Contract, Resubmission of IDE to Treat Hepatitis C (HCV), Biothreat Legislation Signed into Law by President Obama. |
|
|
Apr 16, 2013 |
1542 |
| Switzerland : Roche and Ascletis enter collaboration to advance treatment options for Chinese patients with Hepatitis C. |
|
|
Apr 16, 2013 |
304 |
| Benitec Selects University of California, San Diego as a Site for Phase I/II Clinical Trial of TT-034 in Patients with Hepatitis C Infections. |
|
|
Apr 15, 2013 |
1043 |
| Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress. |
|
|
Apr 8, 2013 |
1275 |
| Specialty drug costs account for more than 50 percent of the total cost of care for rheumatoid arthritis and hepatitis C patients. |
|
|
Apr 2, 2013 |
929 |
| Johnny Delirious Lectures at the Addison Wellness Expo. |
|
|
Mar 28, 2013 |
423 |
| Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C. |
|
|
Mar 28, 2013 |
883 |
| Benitec Selects the Duke Clinical Research Unit as a Site for Hepatitis C Phase I/II Clinical Trial. |
|
|
Mar 21, 2013 |
1024 |
| Expanding High Risk Population Drives European Hepatitis B and C Diagnostics Market, finds Frost & Sullivan. |
|
|
Mar 13, 2013 |
941 |
| Expanding High Risk Population Drives European Hepatitis B and C Diagnostics Market, finds Frost & Sullivan. |
|
|
Mar 13, 2013 |
945 |
| Wendell Potter, Former VP Corporate Communications For Cigna, Testifies In Las Vegas Trial Regarding Role of Health Plan of Nevada In Hepatitis C Outbreak. |
|
|
Mar 6, 2013 |
439 |
| Medivir: Results From a Phase IIa Study Evaluating Simeprevir and Sofosbuvir in Prior Null Responder Hepatitis C Patients Have Been Presented at CROI. |
|
|
Mar 6, 2013 |
2170 |
| US Spending on Traditional Prescription Drugs Fell in 2012 for First Time on Record. |
|
|
Mar 5, 2013 |
1426 |
| Medivir: First interim results from a phase IIa study evaluating an all-oral regimen of Simeprevir and Sofosbuvir in prior null responder Hepatitis C patients. |
|
|
Mar 4, 2013 |
1320 |
| AIDS Advocates to Protest Gilead Sciences over HIV and Hepatitis C Drug Pricing and Policies at C.R.O.I. |
|
|
Mar 4, 2013 |
1353 |
| Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir. |
|
Financial report |
Mar 4, 2013 |
1316 |
| Health Plan of Nevada Credentialing Committee Member Testifies Before Hepatitis C Outbreak He Knew Dr. Desai Claimed To Be Fastest Colonoscopist In Town. |
|
|
Feb 28, 2013 |
348 |
| New Research Report on Hepatitis C Therapeutics Market to 2018 by MarketResearchReports. |
|
|
Feb 27, 2013 |
742 |
| Medivir: Regulatory Application has now been filed for Simeprevir (TMC435) in Japan for the treatment of genotype 1 hepatitis C patients. |
|
|
Feb 22, 2013 |
901 |
| Gilead Turns Tax-Supported Tax-Evader with Hep C Patent in Ireland, Says AHF. |
|
|
Feb 20, 2013 |
525 |
| Australia : Subsidy for Groundbreaking Hepatitis C Treatments. |
|
|
Feb 20, 2013 |
354 |
| HMO To Stand Trial In Las Vegas For Role In Largest Hepatitis C Outbreak In U.S. History. |
|
|
Feb 19, 2013 |
309 |
| I became midlife party animal try and ended up with hepatitis; She thought drugs would help ease the pain of her marriage ending but Janet paid the price for her party days with serious illness. |
|
|
Feb 16, 2013 |
1522 |
| Verification of technical specifications and claims in the context of Support for Market Entry of New HIV Diagnostic Products. |
|
|
Feb 9, 2013 |
178 |
| Spread of hepatitis C pinpointed. |
|
|
Feb 2, 2013 |
564 |
| Hepatitis C cure? |
Henkelman, Wallace J. |
|
Feb 1, 2013 |
153 |
| Medivir: Phase II all-oral combination studies of Simeprevir, TMC647055 and IDX719 for the treatment of Hepatitis C to be initiated shortly. |
|
|
Jan 28, 2013 |
966 |
| Tattoos linked to hepatitis C. |
|
|
Jan 26, 2013 |
428 |
| Tattooing could lead to hepatitis C. |
|
|
Jan 25, 2013 |
313 |
| Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program. |
|
|
Jan 17, 2013 |
1490 |
| Liver Diseases Therapeutics Market is Expected to Reach USD 10.9 Billion Globally in 2018: Transparency Market Research. |
|
|
Jan 16, 2013 |
1267 |
| Economist Intelligence Unit Report Calls for Global Policy Innovation to Tackle the 'Silent Pandemic' That is Hepatitis C. |
|
|
Jan 15, 2013 |
1367 |
| Economist Intelligence Unit Report Calls for Global Policy Innovation to Tackle the 'Silent Pandemic' That is Hepatitis C. |
|
|
Jan 15, 2013 |
1371 |
| Inovio Pharmaceuticals to Initiate Clinical Trial for its Hepatitis C Therapeutic Vaccine (INO-8000) Later this Year. |
|
|
Jan 9, 2013 |
1602 |
| NIH investigators discover new gene that affects clearance of hepatitis C virus. |
|
|
Jan 7, 2013 |
139 |
| Netherlands : Antiviral Therapy of Viral Hepatitis C. |
|
|
Jan 4, 2013 |
151 |
| Hepatitis C Test proving a life saver. |
|
|
Dec 15, 2012 |
294 |
| Medivir announces initiation of the second cohort of the interferon-free phase II study combining Simeprevir and sofosbuvir for hepatitis C treatment. |
|
Clinical report |
Dec 13, 2012 |
729 |
| Though Hepatitis C Patients Report Having Equal Influence with Their Treating Physicians Regarding the Management and Treatment of Their Disease, Very Few Have Ever Requested Specific Products for Treatment. |
|
Clinical report |
Dec 13, 2012 |
689 |
| CAHG Wins Global Award for Third Consecutive Year. |
|
|
Dec 10, 2012 |
852 |
| Aethlon Medical (AEMD) Note: A Medical Device Strategy to Address Metastatic Melanoma. |
|
|
Dec 7, 2012 |
2605 |
| Investigational HCV regimens ditch interferon: the use of direct-acting antivirals frees up drug combinations from peginterferon or ribavirin. |
Osterweil, Neil |
|
Dec 1, 2012 |
1337 |
| High-Tech Medical Consulting from St. Joseph's Helps Native Americans with Hepatitis C. |
|
|
Nov 28, 2012 |
609 |
| Many Physicians who Treat HCV Have Begun 'Warehousing' and Preparing HCV Patients for the Next Generation of Interferon-Free Treatments to Become Available, According to a Recent BioTrends Report. |
|
|
Nov 15, 2012 |
819 |
| Study to Evaluate Safety and Efficacy of Fuzheng Huayu as an Anti-Fibrotic Treatment in U.S. Hepatitis C Patients Nears Completion. |
|
|
Nov 13, 2012 |
484 |
| Abbott Announces Phase 3 Hepatitis C Program Details. |
|
|
Nov 13, 2012 |
983 |
| Abbott Announces Phase 3 Hepatitis C Program Details. |
|
|
Nov 13, 2012 |
1006 |
| Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 Achieved SVR12 of 94% in Treatment-Naove Patients with Genotype 1 Chronic Hepatitis C Infection in Phase II Trial. |
|
|
Nov 12, 2012 |
1465 |
| Bristol-Myers Squibb's Investigational Hepatitis C Compounds Lambda and Daclatasvir Plus Ribavirin Achieved SVR12 in 93% of Genotype 1b Treatment-Naive Patients In Phase IIb Study. |
|
|
Nov 12, 2012 |
3166 |
| Data from Viral Kinetic Study Showed Rapid Reduction of HCV RNA with ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for the Treatment of Hepatitis C. |
|
|
Nov 10, 2012 |
2970 |
| Efficacy and Safety Data from Phase 2B Trials of Janssen's Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases. |
|
|
Nov 10, 2012 |
1467 |
| Efficacy and Safety Data from Phase 2B Trials of Janssen's Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases. |
|
|
Nov 10, 2012 |
1471 |
| Boehringer Ingelheim Launches Hepatitis C Online Resource. |
|
|
Nov 9, 2012 |
917 |
| Six Late-breaking Abstracts Selected for Oral Presentation at The Liver Meeting. |
|
Clinical report |
Nov 2, 2012 |
1199 |
| Chronic hepatitis C: the hidden epidemic. |
Patrick, Lyn |
Report |
Nov 1, 2012 |
5285 |
| Antifibrotic protocol for hepatitis C. |
Abshier, Thomas Lee |
Report |
Nov 1, 2012 |
3657 |
| Vitamin C cures two cases of serious illness. |
|
Clinical report |
Nov 1, 2012 |
376 |
| Janssen Announces Collaboration With Vertex On Phase 2 Study To Investigate An All-Oral Regimen Of Simeprevir (TMC435) And VX-135 For Treatment Of Hepatitis C. |
|
|
Nov 1, 2012 |
991 |
| Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C. |
|
|
Nov 1, 2012 |
997 |
| Hepatitis C drug interactions. |
|
|
Nov 1, 2012 |
209 |
| HCV patients given antivirals have less liver cancer. |
Napoli, Denise |
|
Nov 1, 2012 |
470 |
| A language for integrated care: how Motivational Interviewing and the Stages of Change can reshape delivery--and outcomes--for integrated care. |
Sciacca, Kathleen |
|
Nov 1, 2012 |
2409 |
| Research and Markets: Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy. |
|
|
Oct 24, 2012 |
648 |
| Research and Markets: Hepatitis C - Pipeline Review, H2 2012. |
|
|
Oct 23, 2012 |
386 |
| Hospital wins delay in hep C civil suits. |
|
Brief article |
Oct 19, 2012 |
121 |
| TEST FOR 'SILENT DISEASE'. |
|
|
Oct 18, 2012 |
141 |
| BioCryst Pharmaceuticals and Presidio Pharmaceuticals to Merge. |
|
|
Oct 18, 2012 |
2303 |
| MarketResearchReports.Biz - Hepatitis C - Pipeline Review, H2 2012 - New Market Research Report. |
|
|
Oct 16, 2012 |
1106 |
| Simeprevir (TMC435) Data In Hepatitis C To Be Presented At The Annual Meeting of the American Association for the Study of Liver Diseases. |
|
|
Oct 16, 2012 |
1140 |
| MarketResearchReports.Biz - Hepatitis C - Pipeline Review, H2 2012 - New Market Research Report. |
|
|
Oct 16, 2012 |
1111 |
| Australia : Acquisition of Tacere Therapeutics and Phase I/II ready hepatitis C (HCV) program. |
|
|
Oct 12, 2012 |
439 |
| ISR's Hepatitis C Market Analysis Shows a Deep Pipeline, Uncovers Lack of Internet Search Visibility for Current Therapies. |
|
|
Oct 9, 2012 |
442 |
| Aethlon Medical Releases EXOSOMES & MICROVESICLES 2012 Presentation. |
|
|
Oct 3, 2012 |
764 |
| CDC recommends expanded patient testing: in the 40th year of hepatitis diagnostics, the agency recommends that millions of baby boomers be tested for HCV. |
Dawson, George; Schochetman, Gerald |
|
Oct 1, 2012 |
1610 |
| New cure takes half the time. |
|
Brief article |
Oct 1, 2012 |
305 |
| Vertex Announces New Data on ALS-2200 in People With Hepatitis C, Supporting Advancement into Phase 2 All-Oral Studies in 2012; Ends Development of ALS-2158. |
|
|
Sep 25, 2012 |
2379 |
| Aethlon Medical To Present at the Exosomes and Microvesicles 2012 Conference. |
|
Conference news |
Sep 25, 2012 |
804 |
| Better Hepatitis Drugs Costly for Texas Prisons. |
|
|
Sep 21, 2012 |
1309 |
| A MAN who died of Hepatitis C only found out he had [...]. |
|
|
Sep 21, 2012 |
295 |
| Man got fatal bug from 1983 blood transfusion; DDeeccoorraattoorr lloosseess 3300--yyeeaarr bbaattttllee wwiitthh hheeppaattiittiiss CC. |
|
|
Sep 21, 2012 |
295 |
| Medivir: A phase IIa interferon free combination hepatitis C trial of Simeprevir (TMC435) and TMC647055 will commence shortly. |
|
|
Sep 20, 2012 |
540 |
| A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly. |
|
|
Sep 20, 2012 |
602 |
| A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly. |
|
|
Sep 20, 2012 |
606 |
| Analyte Health Launches New Campaign, Pricing to Encourage Hepatitis C Testing Among Baby Boomers. |
|
|
Sep 20, 2012 |
723 |
| Hep C Rx doesn't mix well with others. |
|
|
Sep 15, 2012 |
162 |
| Research and Markets: Hepatitis C - Pipeline Review, H2 2012. |
|
|
Sep 14, 2012 |
443 |
| Lawsuit Pursuing Hepatitis C Cases Stemming From Hospital Technician Filed by The Shamberg, Johnson & Bergman, Chtd. |
|
|
Sep 10, 2012 |
424 |
| Med tech accused of knowingly spreading hepatitis C is in custody. |
|
|
Sep 1, 2012 |
394 |
| HIV activist passes away. |
|
|
Sep 1, 2012 |
292 |
| CDC urges hepatitis C test for baby boomers. |
Splete, Heidi |
|
Sep 1, 2012 |
310 |
| Metformin for hepatitis C. |
Pryce, A. |
Brief article |
Sep 1, 2012 |
229 |
| Closing the Loop Between Hepatitis C Testing and Care for Baby Boomers. |
|
|
Aug 24, 2012 |
459 |
| Bristol-Myers Squibb Discontinues Development of BMS-986094, an Investigational NS5B Nucleotide for the Treatment of Hepatitis C. |
|
|
Aug 23, 2012 |
426 |
| Major Breakthrough in Hepatitis C Vaccine Development. |
|
|
Aug 13, 2012 |
278 |
| "Hepatitis C, CURED" Authored by Johnny Delirious is in Times Square. |
|
|
Aug 10, 2012 |
629 |
| Bristol-Myers Squibb Suspends Administration of Study Drug in Clinical Trial of Investigational NS5B Nucleotide for the Treatment of Hepatitis C. |
|
|
Aug 2, 2012 |
189 |
| Doctors urge test. |
|
|
Jul 31, 2012 |
182 |
| New Hampshire Hepatitis C Outbreak Suspect David Kwiatkowski Left Suicide Note, Sets Off Hunt For Infected Patients. |
|
|
Jul 30, 2012 |
354 |
| Health experts for timely treatment of hepatitis disease. |
|
Disease/Disorder overview |
Jul 28, 2012 |
516 |
| Increase in infectious disease cases. |
|
|
Jul 27, 2012 |
389 |
| Hepatitis C increase. |
|
|
Jul 27, 2012 |
108 |
| PR pros see crucial missteps in hospital's hep C response: Exeter Hospital 'did not do a good job following the basic rules of crisis communication'. |
Callahan, Kathleen |
|
Jul 27, 2012 |
2034 |
| Bristol-Myers Squibb Foundation Marks World Hepatitis Day 2012 with New Grants Focused on Hepatitis B and Hepatitis C Patient Empowerment in China and India. |
|
|
Jul 26, 2012 |
1169 |
| Deaths linked to hepatitis C rise. |
|
|
Jul 26, 2012 |
120 |
| Research and Markets: Disease and Therapy Review: Hepatitis C (Updated). |
|
|
Jul 26, 2012 |
348 |
| Hepatitis C sub-type 90% curable in Pakistan. |
|
|
Jul 23, 2012 |
537 |
| Hepatitis C sub-type 90% curable in Pakistan. |
|
|
Jul 23, 2012 |
533 |
| NIH scientists identify likely predictors of hepatitis C severity. |
|
Brief article |
Jul 23, 2012 |
128 |
| David Kwiatkowski, A Lab Technician From New Hampshire, Accused Of Causing A Hepatitis C Outbreak And Infecting 30 Patients. |
|
|
Jul 21, 2012 |
318 |
| Milk Thistle Extract Doesn't Help Liver Patients, Trial Finds. |
|
|
Jul 17, 2012 |
401 |
| Hepatitis nurse role evolving. |
|
|
Jul 1, 2012 |
391 |
| Climbing the "ladder of participation": engaging experiential youth in a participatory research project. |
Funk, Anna; Van Borek, Natasha; Taylor, Darlene; Grewal, Puneet; Tzemis, Despina; Buxton, Jane A. |
Report |
Jul 1, 2012 |
3902 |
| Presidio Pharmaceuticals Successfully Completes Phase 1 Proof-of-Concept for PPI-668, its Potent HCV NS5A Inhibitor, in Hepatitis C Patients with Genotype-1 Infection. |
|
|
Jun 26, 2012 |
716 |
| Don't ignore ticking timebomb. |
|
|
Jun 22, 2012 |
145 |
| Research and Markets: Global Hepatitis C Drugs Market 2011-2015 Features Players GlaxoSmithKline plc, Roche Holding Ltd and Merck & Co. Inc. |
|
Industry overview |
Jun 22, 2012 |
367 |
| Incivek and Victrelis Are Important Advances in the Treatment of HCV, Significantly Outperforming Dual Therapy Options; However, Physicians Still Feel There is a High Need for Alternative Therapies to Treat HCV. |
|
|
Jun 19, 2012 |
896 |
| Asia Pacific Infectious Disease Diagnostics Market Overview. |
|
|
Jun 7, 2012 |
913 |
| Asia Pacific Infectious Disease Diagnostics Market Overview. |
|
|
Jun 7, 2012 |
908 |
| Hep C cop spit drunk is caged. |
|
|
May 30, 2012 |
109 |
| MSD offers new treatment for hepatitis C. |
|
|
May 28, 2012 |
478 |
| Since Gaining European Authority Approval for Victrelis in July and Incivo in September, Protease Inhibitor Share Has Penetrated Nearly One-Third of the Genotype 1 Market and is Anticipated to Significantly Increase Over the Next Six Months. |
|
|
May 21, 2012 |
690 |
| "World Hepatitis Treatment and Vaccine Market Will Reach $8.7bn in 2012" Visiongain Report Predicts. |
|
|
May 4, 2012 |
642 |
| Jump on the health bus for blood test. |
|
|
Apr 24, 2012 |
147 |
| Presidio Pharmaceuticals Announces Phase 1a-1b Clinical Results with PPI-668, a Potent Pan-genotypic HCV NS5A Inhibitor. |
|
|
Apr 19, 2012 |
718 |
| Janssen Creates new Division to Launch TMC435 and Help Conquer Hepatitis C in EMEA. |
|
|
Apr 19, 2012 |
1040 |
| Janssen's Commitment to People with Hepatitis C. |
|
|
Apr 19, 2012 |
570 |
| Janssen Creates new Division to Launch TMC435 and Help Conquer Hepatitis C in EMEA. |
|
|
Apr 19, 2012 |
1044 |
| Abbott Presents Positive Results from Interferon-Free Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C. |
|
|
Apr 19, 2012 |
1763 |
| Abbott Presents Positive Results from Phase 2 "Pilot" Study of an Interferon-Free Combination Regimen for the Treatment of Hepatitis C. |
|
|
Apr 19, 2012 |
1537 |
| Vertex Advances INCIVEK[TM] (telaprevir) and Broad Portfolio of Medicines in Development With Goal of Further Expanding and Improving Treatment for People With Hepatitis C. |
|
|
Apr 18, 2012 |
3267 |
| Abbott to Present Positive Phase 2 Results from Multiple Interferon-Free Studies of Combination Regimens for the Treatment of Hepatitis C. |
|
|
Apr 4, 2012 |
1982 |
| Medivir Announces Acceptance of Four TMC435 Abstracts for Presentation at the EASL Meeting. |
|
|
Apr 4, 2012 |
547 |
| Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL. |
|
|
Apr 4, 2012 |
1601 |
| Medivir Announces Acceptance of Four TMC435 Abstracts for Presentation at the EASL Meeting. |
|
|
Apr 4, 2012 |
543 |
| Research and Markets: Advanced Therapy for Hepatitis C. |
|
|
Apr 3, 2012 |
370 |
| Human parvovirus 4 infection, Cameroon. |
Lavoie, Myriam; Sharp, Colin P.; Pepin, Jacques; Pennington, Christopher; Foupouapouognigni, Yacouba |
|
Apr 1, 2012 |
2418 |
| Tuberculosis screening before anti-hepatitis C virus therapy in prisons. |
Babudieri, Sergio; Soddu, Andrea; Murino, Monica; Molicotti, Paola; Muredda, Alberto A.; Madeddu, Gi |
Case study |
Apr 1, 2012 |
1366 |
| Hepatitis c infection on the rise among teens, young adults. |
Worcester, Sharon |
|
Mar 15, 2012 |
507 |
| Research and Markets: Hepatitis C - Pipeline Review, H1 2012. |
|
|
Mar 14, 2012 |
427 |
| Egyptians design 'faster, cheaper' hepatitis C test. |
|
|
Mar 14, 2012 |
306 |
| Liver Transplant Program at Methodist Specialty and Transplant Hospital Recognized as Best in the Nation. |
|
|
Mar 14, 2012 |
586 |
| Hepatitis C (HCV) treatment is not a "one size fits all". |
Bukeirat, Faisal A.; Bukeirat, Mimi M. |
Report |
Mar 1, 2012 |
2304 |
| Bristol-Myers Squibb Foundation Announces Grants Focused on Prevention, Diagnosis and Care of Hepatitis B and Hepatitis C in Asia. |
|
|
Feb 18, 2012 |
951 |
| Gilead Announces Data for Genotype 1 Null Responder Hepatitis C Patients Enrolled in ELECTRON Study. |
|
Clinical report |
Feb 17, 2012 |
898 |
| BioCryst Announces Promising Results from Preclinical Studies of BCX5191 for Hepatitis C. |
|
|
Feb 15, 2012 |
1100 |
| asktheDoc. |
|
|
Feb 14, 2012 |
224 |
| MAJOR breakthroughs in the treatment [...]. |
|
|
Feb 13, 2012 |
169 |
| Culture: Impact of war on language (155). |
|
|
Feb 6, 2012 |
630 |
| Aethlon Medical Reports Immediate and Rapid Virologic Responses in Hepatitis C (HCV) Patients Receiving Hemopurifier[R] Treatment Protocol. |
|
|
Feb 1, 2012 |
2200 |
| Combination of Oral Drugs Suppresses Common Type of Hepatitis C, According to University of Michigan-led Research. |
|
|
Jan 19, 2012 |
969 |
| College's drug find triggers pounds 1.6bn buy-out. |
|
|
Jan 11, 2012 |
330 |
| Vertex Announces Key 2012 Business Objectives as Company Prepares for Planned Global Launch of KALYDECO in Cystic Fibrosis. |
|
|
Jan 9, 2012 |
2454 |
| A COUSIN of the common [...]. |
|
|
Jan 9, 2012 |
222 |
| Cold clue to vaccine for hepatitis C; HEALTH. |
|
|
Jan 5, 2012 |
161 |
| Obesity and hepatitis C infection ups fatal liver cancer risk. |
|
|
Jan 4, 2012 |
433 |
| Research and Markets: Hepatitis C Global Clinical Trials Review, H2, 2011. |
|
|
Jan 4, 2012 |
341 |
| Can-Fite BioPharma Announces Successful Results of its Phase I/II Liver Cancer Study with its CF102 Drug; the Study Achieved the Primary and Secondary Endpoints. |
|
Report |
Jan 3, 2012 |
904 |
| Diabetes quadruples hospitalizations for liver disease. |
London, Susan |
|
Jan 1, 2012 |
558 |
| Telaprevir not cost effective for all hepatitis C patients. |
Otto, M. Alexander |
|
Jan 1, 2012 |
766 |
| Incivek and Victrelis Usage as Part of Triple Therapy Hepatitis C Regimen is Emerging as the New Standard of Care for Genotype 1 Patients According to a Newly Released Report by BioTrends Research Group. |
|
|
Dec 22, 2011 |
584 |
| Drug linked to hepatitis C infections. |
|
|
Dec 22, 2011 |
145 |
| Vertex and Alios BioPharma Begin Clinical Studies of Nucleotide Drug Candidates ALS-2200 and ALS-2158 for the Treatment of Hepatitis C. |
|
|
Dec 9, 2011 |
2332 |
| Dendreon Agrees to Sell VICTRELIS[TM] (boceprevir) Royalty Interest for $125 Million. |
|
|
Dec 6, 2011 |
720 |
| Egypt team wins at Intel challenge for Hepatitis C detection. |
|
|
Nov 17, 2011 |
521 |
| Medivir: Key News from the Ongoing Capital Markets Day. |
|
|
Nov 15, 2011 |
859 |
| Universal screening for HCV? |
Golden, William E. |
|
Nov 15, 2011 |
266 |
| Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&D and Business Briefing. |
|
|
Nov 10, 2011 |
1385 |
| Medgenics Provides Clinical and Regulatory Update. |
|
|
Nov 9, 2011 |
1176 |
| 12-Week On-Treatment Results from Large Phase IIb Study (COMMAND-1) of Bristol-Myers Squibb's NS5A Inhibitor Daclatasvir Support Anti-HCV Activity and Safety Profile Observed in Earlier Studies. |
|
|
Nov 8, 2011 |
1527 |
| Cytheris Announces Interim Results from ECLIPSE 2 Hepatitis C Multicenter Study of IL-7 in Chronically Infected Genotype 1 and 4 Nonresponders to Standard of Care (SOC). |
|
|
Nov 8, 2011 |
1455 |
| Records Show Deaths Associated With Hepatitis C Have Overtaken Deaths Caused by HIV. |
|
|
Nov 8, 2011 |
459 |
| Medivir's partner Tibotec announced that final SVR24 results from phase IIb PILLAR study of TMC435 will be presented at the AASLD meeting today. |
|
Clinical report |
Nov 7, 2011 |
1528 |
| All-Oral Treatment Regimen of Bristol-Myers Squibb's Investigational NS5A and NS3 Inhibitors Achieved 90% Sustained Virologic Response (SVR12) in Phase II Study Sentinel Cohort of Genotype 1b Null Responders. |
|
Clinical report |
Nov 7, 2011 |
1253 |
| New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1. |
|
|
Nov 4, 2011 |
1376 |
| New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1. |
|
|
Nov 4, 2011 |
1489 |
| Vertex Announces Recipients of Special Grants Initiative to Support People with Hepatitis C. |
|
|
Nov 4, 2011 |
1879 |
| Medivir Announces Final Results from TMC435 Phase IIb ASPIRE (C206) Study. |
|
|
Nov 2, 2011 |
1879 |
| Molecular diagnostics is a game changer for hospital labs. |
Groody, Patrick |
|
Nov 1, 2011 |
969 |
| Research and Markets: Hepatitis C - Pipeline Review, H2 2011. |
|
|
Oct 28, 2011 |
423 |
| Cytheris to Present Interim Data from ECLIPSE 2 Hepatitis C Multicenter Study at AASLD Annual Meeting. |
|
|
Oct 26, 2011 |
652 |
| Research and Markets: U.S. Hepatitis C Market. |
|
|
Oct 21, 2011 |
296 |
| U.S. Hepatitis C Market. |
|
|
Oct 20, 2011 |
361 |
| GRAMMY Winner Natalie Cole to Spotlight Hepatitis C Campaign at National Press Club, Oct. 19. |
|
|
Oct 17, 2011 |
644 |
| Companies team up for trail ride. |
|
|
Oct 12, 2011 |
180 |
| New 'wonder' pill set to revolutionise hepatitis C treatment. |
|
|
Oct 12, 2011 |
281 |
| Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C. |
|
|
Oct 10, 2011 |
1140 |
| Hepatitis C Landscape is Changing as the New Protease Inhibitors are Adopted into Clinical Practice. |
|
|
Oct 6, 2011 |
736 |
| Renal-sparing immunosuppressive protocol using OKT3 after liver transplantation: a 19-year single-institution experience. |
Kim, Peter T.W.; Chinnakotla, Srinath; Davis, Gary; Jennings, Linda W.; McKenna, Greg J.; Onaca, Nic |
Report |
Oct 1, 2011 |
5658 |
| Short telaprevir regimen trumps longer one. |
Mahoney, Diana |
|
Oct 1, 2011 |
589 |
| The effects of raw and physical processed common vetch seed (Vicia sativa) on laying performance, egg quality, metabolic parameters and liver histopatology of laying hens. |
Kaya, H.; Celebi, S.; Macit, M.; Geyikoglu, F. |
Report |
Sep 28, 2011 |
5840 |
| Updated Hepatitis C Practice Guidelines Now Available from AASLD. |
|
|
Sep 28, 2011 |
780 |
| New Treatment for Hepatitis C Helps Boost Cure Rate. |
|
|
Sep 21, 2011 |
382 |
| GRAMMY Winner Natalie Cole to Spotlight Hepatitis C Campaign at National Press Club, Oct. 19. |
|
|
Sep 21, 2011 |
653 |
| BMS-790052 Plus Peginterferon Alfa and Ribavirin Demonstrated up to 83% Sustained Virologic Response 24 Weeks Post-Treatment (SVR24) in Phase II Study of Genotype 1 Hepatitis C Patients. |
|
Report |
Sep 17, 2011 |
1252 |
| Anadys Pharmaceuticals Updates Its Presentation Date at the Stifel Nicolaus Healthcare Conference. |
|
Conference news |
Sep 6, 2011 |
596 |
| Gilead Amends Study Design for Ongoing Hepatitis C Clinical Trials That Include GS 9190, Pegylated Interferon and Ribavirin, and Another Direct-Acting Antiviral Agent. |
|
|
Sep 4, 2011 |
601 |
| Medivir: Completed Enrollment of Three Global Phase 3 Trials for TMC435 in Chronic Hepatitis C Genotype-1 Infected Patients. |
|
|
Aug 31, 2011 |
837 |
| Patient Advocate Foundation Announces Additional Support for Patient Co-Pay Relief Program Serving Breast Cancer, Colon Cancer, Hepatitis C Patients. |
|
|
Aug 22, 2011 |
705 |
| A NEW pill that directly [...]. |
|
|
Aug 15, 2011 |
223 |
| Hepatitis C victim had life 'robbed' InqUESt. |
|
|
Aug 11, 2011 |
150 |
| Pill launched to target hepatitis C. |
|
|
Aug 10, 2011 |
106 |
| First effective treatment for most common form of Hepatitis C launched. |
|
|
Aug 10, 2011 |
271 |
| Hepatitis C Specialists Report Similar Trial Rates for Merck/Roche's Victrelis and Vertex's Incivek, but Incivek is Likely to Claim a Significant Share Advantage in the Coming Months According to Results from New LaunchTrends Study. |
|
|
Aug 8, 2011 |
555 |
| Scientists a step closer to Hepatitis C vaccine. |
|
|
Aug 5, 2011 |
536 |
| New approach lifts hope for hepatitis C vaccine. |
|
|
Aug 4, 2011 |
315 |
| Hepatitis C on rise. |
|
|
Aug 1, 2011 |
205 |
| FESTIVAL-GOERS are being warned this [...]. |
|
|
Aug 1, 2011 |
265 |
| Acute hepatitis C outbreak among HIV-infected men, Madrid, Spain. |
Montoya-Ferrer, Ana; Fierer, Daniel Seth; Alvarez-Alvarez, Beatriz; de Gorgolas, Miguel; Fernandez-G |
Letter to the editor |
Aug 1, 2011 |
1372 |
| Powerful data' challenge leaders. |
Amon, Joseph J. |
Brief article |
Aug 1, 2011 |
234 |
| State's high court ruled 'rebuttal' testimony by nurse admissible. |
|
|
Aug 1, 2011 |
832 |
| Must educate drug users on Hepatitis C. |
|
|
Jul 28, 2011 |
394 |
| Hep C cases on rise in region. |
|
|
Jul 28, 2011 |
208 |
| NCCVH calls for unified efforts to raise funds for hepatitis C. |
|
|
Jul 28, 2011 |
380 |
| Youth warned of health risks in tattooing, body piercing. |
|
|
Jul 27, 2011 |
613 |
| Interim Data from Phase 2 Study of Combination Regimen Including VX-222 and INCIVEK[TM] Suggest Potential to Treat Genotype 1 Hepatitis C in as few as 12 Weeks and No More Than 24 Weeks. |
|
|
Jul 26, 2011 |
3161 |
| SMCs Alumni to hold public awareness campaign against Hepatitis. |
|
|
Jul 24, 2011 |
159 |
| PURE Bioscience Obtains U.S. EPA Registration of Expanded Claims for PURE Hard Surface Disinfectant/Sanitizer. |
|
|
Jul 21, 2011 |
1312 |
| Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C. |
|
|
Jul 20, 2011 |
1861 |
| Walgreens Specialty Pharmacy Drives Adherence for Hepatitis C Patients Through Therapy Management Program. |
|
|
Jul 18, 2011 |
845 |
| Birch bark extract as therapy for chronic hepatitis C--a pilot study. |
Shikov, Alexander N.; Djachuk, Georgy I.; Sergeev, Dmitry V.; Pozharitskaya, Olga N.; Esaulenko, Ele |
Report |
Jul 15, 2011 |
3508 |
| Medco's Specialty Pharmacy Improves Hepatitis C Patient Outcomes, Drives Down Costs by an Average $13,000 Per Patient. |
|
|
Jul 5, 2011 |
1110 |
| Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation. |
O'Leary, Jacqueline G.; Trotter, James F.; Neri, Michael A.; Jennings, Linda W.; McKenna, Greg J.; D |
Report |
Jul 1, 2011 |
3481 |
| HEALTH SECTOR -Turkish cure to Hepatitis C and AIDS. |
|
|
Jul 1, 2011 |
295 |
| Popular Nonprofit Organization Falls Victim to Economic Downturn. |
|
|
Jun 22, 2011 |
464 |
| Massive Opportunity Exists in Hepatitis C Market for Recently Approved Protease Inhibitors Victrelis and Incivek According to a New Report by BioTrends Research Group. |
|
|
Jun 13, 2011 |
555 |
| Mortality from all causes higher among hepatitis C-infected. |
|
|
Jun 11, 2011 |
374 |
| Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C. |
|
|
Jun 8, 2011 |
1041 |
| 3 or more cups of coffee a day doubles hepatitis C treatment response. |
|
Clinical report |
Jun 8, 2011 |
218 |
| CVS Caremark Enhances Hepatitis C Support Program to Help Patients Manage New Triple Therapy Regimen. |
|
|
Jun 3, 2011 |
658 |
| HCV rapid test uses fingerstick whole blood. |
|
Brief article |
Jun 1, 2011 |
114 |
| FDA approved Vertex Pharmaceutical's Incivek for treating people with chronic hepatitis C. |
|
|
Jun 1, 2011 |
243 |
| FDA approves second hep C agent. |
|
|
Jun 1, 2011 |
182 |
| Research and Markets: Telaprevir and Boceprevir: The First Generation Protease Inhibitors Boosts Response Rates to Standard Chronic Hepatitis C Treatment. |
|
|
May 31, 2011 |
328 |
| FDA approves Incivek for hepatitis C. |
|
|
May 23, 2011 |
1088 |
| Medivir Announces Positive 48-week Interim Data from TMC435 Hepatitis C Phase 2b ASPIRE Study in Treatment-Experienced Genotype-1 Patients. |
|
Clinical report |
May 20, 2011 |
1754 |
| Higher Rebates and Discounts Have Greater Influence on Reimbursement Status for Hepatitis C Therapies Than Superior Clinical Attributes. |
|
|
May 19, 2011 |
554 |
| Abbott Receives FDA Approval for Molecular Test for Hepatitis C. |
|
|
May 18, 2011 |
1019 |
| VIDEO from Abbott and Synaptic Digital: Abbott Receives FDA Approval for Molecular Test for Hepatitis C. |
|
|
May 18, 2011 |
441 |
| FDA Approves Victrelis for Hepatitis C. |
|
|
May 13, 2011 |
843 |
| Merck Announces Hope Against Hepatitis C Initiative to Support Public Awareness, Education and Research in the Fight Against Hepatitis C Virus. |
|
|
May 9, 2011 |
1115 |
| Aethlon Medical Discloses FDA Meeting Request and Proposed Expansion of U.S. Treatment Indications to Include Hepatitis C Virus (HCV). |
|
|
May 9, 2011 |
2017 |
| Age-Based Screening for Hepatitis C Virus Could Lead to Fewer Cases of Advanced Liver Disease and Related Deaths, According to New Study. |
|
Report |
May 9, 2011 |
1236 |
| Vertex Pharma Hepatitis C Drug Incivek Likely to be Approved by May 23: Analyst. |
|
|
May 4, 2011 |
451 |
| Trading of Vertex Common Stock Halted Today. |
|
|
Apr 28, 2011 |
1366 |
| FDA Advisory Committee Unanimously Recommends Approval of Telaprevir for People with Hepatitis C. |
|
|
Apr 28, 2011 |
1876 |
| ACHILLION CHRONIC HEPATITIS TREATMENT GETS GOOD RESULTS. |
|
|
Apr 27, 2011 |
926 |
| VICTRELIS[TM] (boceprevir) Unanimously Recommended for Approval by FDA Advisory Committee for Treatment of Chronic HCV Genotype 1 Infection. |
|
|
Apr 27, 2011 |
920 |
| Boehringer Ingelheim Announces Enrollment of First Patient in Phase 3 Trial for Lead Hepatitis C Compound. |
|
|
Apr 26, 2011 |
1344 |
| AGA Digestive Health Outcomes Registry(TM), Powered by MedAssurant Healthcare Data Analytics, Announces New Research Partner. |
|
|
Apr 26, 2011 |
778 |
| Idera Pharmaceuticals Delays Initiation of Phase 2 Clinical Trial of IMO-2125 in Treatment-Naove HCV Patients. |
|
|
Apr 22, 2011 |
799 |
| Inovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C. |
|
Clinical report |
Apr 18, 2011 |
1807 |
| Aethlon Medical Discloses Interview on Therapeutic Strategies to Address Hepatitis C (HCV) and HIV. |
|
|
Apr 15, 2011 |
891 |
| THINK TWICE; Tattoo party warning. |
|
|
Apr 11, 2011 |
302 |
| New Analysis Finds Antidepressants Boost Patient Adherence to Hepatitis C Treatment. |
|
|
Apr 11, 2011 |
932 |
| Inhibitex Announces Proposed Public Offering. |
|
|
Apr 6, 2011 |
682 |
| Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data From Phase 2 Study of ABT-450/r for Treatment of Hepatitis C. |
|
Clinical report |
Apr 4, 2011 |
1343 |
| Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data From Phase 2 Study of ABT-450/r for Treatment of Hepatitis C. |
|
Clinical report |
Apr 4, 2011 |
1350 |
| Investigational Compound PEG-Interferon Lambda Achieved Higher Response Rates with Fewer Flu-Like and Musculoskeletal Symptoms and Cytopenias Than PEG-Interferon Alfa in Phase IIb Study of 526 Treatment-Naive Hepatitis C Patients. |
|
|
Apr 2, 2011 |
1707 |
| Medivir: Week 24 Interim Results From TMC435 Hepatitis C Phase 2b ASPIRE Study Presented at EASL. |
|
Clinical report |
Apr 1, 2011 |
1565 |
| First Vaccine for Viral Hepatitis C Could Become a Reality. |
|
|
Apr 1, 2011 |
783 |
| Cirrhosis, cancer burden increase in hepatitis C. |
Moon, Mary Ann |
|
Apr 1, 2011 |
585 |
| HCV infection as an emerging sexually transmitted disease. |
Marcus, Julia L.; Katz, Kenneth A. |
|
Apr 1, 2011 |
2113 |
| Hope for liver patients; UMass tests drug to prevent re-infection after transplants. |
|
|
Mar 31, 2011 |
829 |
| Inhibitex Announces Data Presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL). |
|
|
Mar 31, 2011 |
284 |
| Drug cocktail shows promise against hepatitis C. |
|
|
Mar 31, 2011 |
296 |
| Investigational Direct-Acting Antiviral BMS-790052 Plus PEG-Interferon Alfa and Ribavirin Achieved Up to 92% Sustained Virologic Response in Phase II Dose-Ranging Study of Treatment-Naove Hepatitis C Patients. |
|
|
Mar 31, 2011 |
1179 |
| New Data Shows 83% of Patients With Genotype 1 Hepatitis C, Who Have Previously Relapsed on Existing Standard of Care Treatments, Achieve a Cure With Investigational Agent Telaprevir[1]. |
|
Clinical report |
Mar 31, 2011 |
789 |
| Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes. |
|
|
Mar 30, 2011 |
851 |
| Tibotec Advances Global Clinical Research Program for TMC435 in HCV; Will Present Four Abstracts Evaluating Safety and Efficacy at EASL. |
|
|
Mar 29, 2011 |
801 |
| Source Precision Medicine, Inc. d/b/a Source MDx Announces 16 Molecular Diagnostic Development Programs Will Be Offered for Sale on April 29, 2011. |
|
|
Mar 29, 2011 |
293 |
| The Majority of Surveyed Gastroenterologists and Surveyed MCO Pharmacy Directors Identified peg-IFN-alpha-2a/ribavirin as the Most Efficacious Therapy for Hepatitis C Virus, When Compared to Other Available Therapies. |
|
|
Mar 24, 2011 |
826 |
| China's Hepatitis C Virus Market Will Grow to $247 Million in 2015. |
|
|
Mar 24, 2011 |
565 |
| Criminalizing HIV transmission and exposure in Canada: a public health evaluation. |
Drummond, Sarah L. |
|
Mar 22, 2011 |
6608 |
| Clinical trial offers hope for Hepatitis C patients. |
|
|
Mar 16, 2011 |
317 |
| Inovio Pharmaceuticals' Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovio's Electroporation Delivery Technology. |
|
|
Mar 14, 2011 |
1417 |
| Hepatitis C payout ruling is welcomed. |
|
|
Mar 11, 2011 |
157 |
| Idera Pharmaceuticals Announces IMO-2125 Data Presentation at the 46th Annual Meeting of the European Association for the Study of the Liver. |
|
|
Mar 8, 2011 |
664 |
| Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference. |
|
Conference news |
Mar 1, 2011 |
529 |
| Distribution pattern of HCV genotypes & its association with viral load. |
Chakravarti, Anita; Dogra, Gaurav; Verma, Vikas; Srivastava, Amit Parkash |
Clinical report |
Mar 1, 2011 |
3410 |
| Hepatitis C infection among pregnant women in British Columbia: reported prevalence and critical appraisal of current prenatal screening methods. |
Blasig, Audrey; Wagner, Emily C.; Pi, David; Bigham, Mark; Remple, Valencia P.; Craib, Kevin J.P.; D |
Report |
Mar 1, 2011 |
4493 |
| New vaccine technology shows promise against hepatitis C virus. |
|
|
Feb 25, 2011 |
467 |
| Medivir Announces Positive Phase 2b 48-week (SVR24) Interim Results of TMC435 in Treatment-Naive Patients Chronically Infected With Genotype-1 Hepatitis C Virus. |
|
Clinical report |
Feb 22, 2011 |
1498 |
| Research and Markets: Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets. |
|
|
Feb 21, 2011 |
1513 |
| Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 in Adults With Chronic Genotype 1 HCV. |
|
|
Feb 18, 2011 |
1422 |
| Reportlinker Adds Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets. |
|
|
Feb 17, 2011 |
818 |
| Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV). |
|
|
Feb 17, 2011 |
668 |
| Efforts needed to eradicate Hepatitis C Virus. |
|
|
Feb 12, 2011 |
439 |
| Inhibitex Receives Fast Track Designation for INX-189 for the Treatment of Chronic Hepatitis C Infections. |
|
|
Feb 11, 2011 |
909 |
| Medivir Announces Start of Phase 1a Trial of the Hepatitis C Polymerase Inhibitor TMC649128. |
|
|
Feb 10, 2011 |
597 |
| Medivir Announces Start of Phase 1a Trial of the Hepatitis C Polymerase Inhibitor TMC649128. |
|
|
Feb 10, 2011 |
641 |
| Anadys Pharmaceuticals to Present at the Bio CEO & Investor Conference. |
|
Conference news |
Feb 8, 2011 |
530 |
| OH BOY! GEORGE TURNS JONATHAN INTO GOTH ICON. |
|
|
Feb 6, 2011 |
371 |
